Skip to Content
Merck
CN
  • Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.

Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.

Clinical therapeutics (2014-09-23)
Peter L Thompson, Freek W A Verheugt
ABSTRACT

Atrial fibrillation (AF) and coronary heart disease (CHD) commonly occur together. Previous consensus guidelines were published before the wide availability of novel oral anticoagulants (NOACs) and newer P2Y12 antiplatelet agents. We examine recent evidence to guide management in 3 categories of patients with AF and CHD: patients with stable CHD, nonstented patients with recent acute coronary syndrome, and patients with a coronary stent requiring dual-antiplatelet therapy. We conducted a literature search by evaluation of PubMed and other data sources including international meeting reports. We critically reviewed recent clinical trial and relevant registry evidence to update European and US consensus documents. Oral anticoagulation with warfarin or NOACs is required to prevent embolic stroke in AF, and antiplatelet therapy is insufficient for this purpose. Antiplatelet therapy using monotherapy with aspirin is the standard of care in stable CHD. Dual-antiplatelet therapy with aspirin and clopidogrel or a new P2Y12 inhibitor (dual-antiplatelet therapy) is needed to reduce coronary events after an acute coronary syndrome or after percutaneous coronary intervention. Combinations of these agents increase the risk of bleeding, and limited clinical trial evidence suggests that withdrawal of aspirin may reduce bleeding without increasing coronary events. Available clinical trials and registries provide remarkably little evidence to guide difficult clinical decision making in patients with combined AF and CHD. In patients on triple antithrombotic therapy with vitamin K antagonists, aspirin, and clopidogrel, a single clinical trial indicates that withdrawal of aspirin may reduce bleeding risk without increasing the risk of coronary thrombosis. It is unclear whether this evidence applies to combinations of NOACs and newer P2Y12 inhibitors. Clinical trials of combinations of the newer antithrombotic agents are urgently needed to guide clinical care.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Acetylsalicylic acid, ≥99.0%
Supelco
Warfarin, analytical standard
Sigma-Aldrich
Acetylsalicylic acid, analytical standard
Supelco
Warfarin, PESTANAL®, analytical standard
Acetylsalicylic acid, European Pharmacopoeia (EP) Reference Standard
Acetylsalicylic acid for peak identification, European Pharmacopoeia (EP) Reference Standard
USP
Warfarin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Aspirin, meets USP testing specifications
Supelco
Aspirin (Acetyl Salicylic Acid), Pharmaceutical Secondary Standard; Certified Reference Material
USP
Aspirin, United States Pharmacopeia (USP) Reference Standard